MPT-0118 is under clinical development by Monopteros Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MPT-0118’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MPT-0118 overview
MPT-0118 is under development for the treatment of advanced or metastatic refractory solid tumors, chordoma, gastric cancer, breast cancer. It is administered through oral route and acts by targeting mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1).
Monopteros Therapeutics overview
Monopteros Therapeutics is a biotechnology company that is engaged in the research and development of inhibitor cells. It conducts clinical trials on reprogramming regulatory T cells in solid tumors. The company is headquartered in Rockport, Massachusetts, the US.
For a complete picture of MPT-0118’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
